Ipilimumab: a promising immunotherapy for melanoma.

Oncology (Williston Park, N.Y.)

Volumn 24, Issue 14, 2010, Pages 1280-1288

  Thumar, Jaykumar R ^a   Kluger, Harriet M ^b  

^a YALE CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); COLITIS; DIARRHEA; DRUG ADMINISTRATION; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CLINICAL TRIALS AS TOPIC; COLITIS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 79952269861     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)